drugset / Trial / NCT00132418

Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders

NCT00132418

Phase 4 Completed 564 enrolled Amgen Immunex Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study was to evaluate the safety of Enbrel (etanercept) in rheumatoid arthritis (RA) subjects with greater than or equal to 1 documented comorbid disease (diabetes mellitus; chronic pulmonary disease; pneumonia within the last year; or recurrent bronchitis, sinusitis, or urinary tract infection) that might increase infection risk.

Timeline

Start
2000-04
Primary completion
2004-02
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg

Indications